1. Home
  2. RNAZ vs SNOA Comparison

RNAZ vs SNOA Comparison

Compare RNAZ & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$6.00

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.09

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAZ
SNOA
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.1M
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
RNAZ
SNOA
Price
$6.00
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.9K
157.6K
Earning Date
04-15-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,288,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.19
52 Week Low
$5.56
$0.85
52 Week High
$20.99
$6.92

Technical Indicators

Market Signals
Indicator
RNAZ
SNOA
Relative Strength Index (RSI) 22.37 35.11
Support Level N/A $0.85
Resistance Level $9.37 $1.23
Average True Range (ATR) 0.62 0.06
MACD -0.09 0.03
Stochastic Oscillator 17.48 40.00

Price Performance

Historical Comparison
RNAZ
SNOA

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: